Lifecore BiomedicalLFCR -3.78%55 OCF Margin % is 20.26% as of Mar. 2026, which is 1216% above its 10-year median of 1.54. GuruFocus rates LFCR with a GF Score™ of 55/100 and a GF Value™ of $6.52 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Lifecore Biomedical ranks better than 59.94% on this metric.
The historical rank and industry rank for Lifecore Biomedical's OCF Margin % or its related term are showing as below:
LFCR'
s OCF Margin % Range Over the Past 10 Years
Min: -20.3 Med: 1.54 Max: 16.33
Current: 13.01
During the past 13 years, the highest OCF Margin % of Lifecore Biomedical was 16.33%. The lowest was -20.30%. And the median was 1.54%.
LFCR's OCF Margin % is ranked better than 59.94% of 956
companies
in the Drug Manufacturers industry
Industry Median: 9.985
vs LFCR: 13.01
Lifecore Biomedical OCF Margin % Related Terms
Lifecore Biomedical OCF Margin % Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lifecore Biomedical (LFCR) has a OCF Margin % of 20.26% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lifecore Biomedical and its competitors. This is 1216% above median its historical median of 1.54. According to the industry distribution chart, Lifecore Biomedical ranks #383 out of 956 companies in the Drug Manufacturers industry, placing it in the top 40.1%.
Is Lifecore Biomedical's OCF Margin % too high?
Lifecore Biomedical's current OCF Margin % of 20.26% is 1216% above median its 10-year median of 1.54. The Drug Manufacturers industry median OCF Margin % is 9.99. Lifecore Biomedical's value of 20.26% is 102.9% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #383 out of 956 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's OCF Margin % compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #383 out of 956 companies for OCF Margin %. This puts Lifecore Biomedical in the upper half of its industry. The industry median OCF Margin % is 9.99. Lifecore Biomedical's value of 20.26% is 102.9% above this benchmark. While the company's 10-year median is 1.54 vs. the industry median of 9.99, Lifecore Biomedical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 9.99, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current OCF Margin % of 20.26% is 102.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 9.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current OCF Margin % is 20.26%, which is 1216% above median its own 10-year median of 1.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.52, compared to a current price of $4.97 — trading 23.8% below its estimated fair value. The current OCF Margin % is 20.26%, which is 1216% above median its 10-year median of 1.54 and 102.9% above the Drug Manufacturers industry median of 9.99. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current OCF Margin % is 20.26% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.97 is trading 23.8% below its estimated GF Value™ of $6.52.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
OCF Margin %: 20.26% (1216% above median its 10-year median of 1.54)
GF Value™: $6.52 vs. price of $4.97 (23.8% below fair value)
Industry Position: 102.9% above the Drug Manufacturers median (#383 of 956)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
